| Literature DB >> 15936970 |
David Burgner1, Anthony Harnden.
Abstract
Kawasaki disease (KD) is an important and common inflammatory vasculitis of early childhood with a striking predilection for the coronary arteries. It is the predominant cause of paediatric acquired heart disease in developed countries. Despite 40 years of research, the aetiology of KD remains unknown and consequently there is no diagnostic test and treatment is non-specific and sub-optimal. The consensus is that KD is due to one or more widely distributed infectious agent(s), which evoke an abnormal immunological response in genetically susceptible individuals. The epidemiology of KD has been extensively investigated in many populations and provides much of the supporting evidence for the consensus regarding etiology. These epidemiological data are reviewed here, in the context of the etiopathogenesis. It is suggested that these data provide additional clues regarding the cause of KD and may account for some of the continuing controversies in the field.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15936970 PMCID: PMC7110839 DOI: 10.1016/j.ijid.2005.03.002
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Diagnostic criteria for Kawasaki disease (for a detailed discussion of the clinical diagnosis and additional clinical features, see references5, 6, 97).
| Fever of at least five days duration plus at least four of the following features: |
| Polymorphous rash |
| Bilateral non-purulent conjunctivitis |
| Changes in the peripheries |
| Oropharyngeal changes |
| Cervical lymphadenopathy |
Treatment of Kawasaki disease (for detailed discussion of the treatment of Kawasaki disease see references5, 6, 97).
| 1. | At a dose of 2 g/kg given as a single infusion over 10–12 hours (unless cardiac status necessitates infusing the dose more slowly or in divided doses). Failure to respond to this initial IVIG dose is usually treated with a second dose (usually 2 g/kg as a single infusion). Failure to respond to the second IVIG dose is often treated with intravenous methylprednisolone under expert supervision |
| 2. | The dose of aspirin is controversial and its utility has never been proven in a randomised controlled trial. It remains, however, part of the standard management of KD. Generally ‘high dose’ aspirin (50–100 mg/kg/day in divided doses) is given acutely until the fever defervesces, when ‘low dose’ aspirin (2–5 mg/kg/day) is given until an echocardiogram at six weeks after the KD diagnosis is normal. If the six week echocardiogram is abnormal, aspirin is usually continued under cardiological supervision |
| 3. | Anti-cytokine therapies and other interventions are generally unproven but have occasionally been used. For a review see Newburger and Fullton |
Proposed but unproven causes of Kawasaki disease.
| Putative etiological agent/environmental association | References |
|---|---|
| Adenovirus | |
| Herpesvirus | |
| Mycoplasma species | |
| Toxigenic streptococci | |
| Viridans streptococci | |
| Toxigenic staphylococci | |
| Rickettsia species | |
| Epstein Barr virus | |
| Retrovirus | |
| Human coronavirus New Haven | |
| Measles virus | |
| House dust mite | |
| Mercury | |
| Carpet shampoo | |
| Residence near body of water |